XPPen Unveils Stunning New Artist 12 3rd with X-Dial Shortcut Keys and Upgraded X4 Smart Chip Stylus

6 months ago

LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- XPPen today unveiled the groundbreaking Artist 12 3rd, a new dial shortcut portable display…

TUMI INVITES YOU TO “GIFT JOY” THIS HOLIDAY SEASON

6 months ago

Discover timeless gifts that celebrate craftsmanship, purpose, and the beauty of detail. NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Today,…

NYSE Content Advisory: Pre-Market Update + 2025 3M Young Scientist Rings Opening Bell

6 months ago

NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

ST Engineering iDirect Announces General Availability of Intuition Ground System

6 months ago

Cloud-native architecture and high-density baseband processing improves operational efficiency, performance and TCO HERNDON, Va., Oct. 20, 2025 /PRNewswire/ -- ST Engineering…

KuCard and Plaza Premium Lounge Announce Partnership to Advance Crypto Integration in Travel Services

6 months ago

PROVIDENCIALES, Turks and Caicos Islands, Oct. 20, 2025 /PRNewswire/ -- KuCard, a Visa card issued by cryptocurrency exchange KuCoin, today announced…

Dubai advances position as Middle East, Africa and South Asia’s leading global financial centre

6 months ago

DUBAI, UAE, Oct. 20, 2025 /PRNewswire/ -- Dubai continues to advance its position as the Middle East, Africa and South…

Fruit Attraction 2025 Strengthens Its Global Leadership with a Record 121,137 Trade Professionals

6 months ago

MADRID, Oct. 20, 2025 /PRNewswire/ -- Fruit Attraction 2025, organised by IFEMA MADRID and FEPEX, closed its 17th edition with…

IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

6 months ago

October 20, 2025 02:30 ET  | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

6 months ago

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

6 months ago

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12…